[1]
|
Steven, C., et al. (2015) Campbell-Walsh Urology. 11th Edition, Elsevier, Amsterdam, 1320-1321.
|
[2]
|
Capitanio, U., et al. (2019) Epidemiology of Renal Cell Carcinoma. European Urology, 75, 74-84.
https://doi.org/10.1016/j.eururo.2018.08.036
|
[3]
|
Tahbaz, R., et al. (2018) Prevention of Kidney Cancer Incidence and Recurrence: Lifestyle, Medication and Nutrition. Current Opinion in Urology, 28, 62-79. https://doi.org/10.1097/MOU.0000000000000454
|
[4]
|
Sung, H., Ferrlay, J., Siegel, R.L., et al. (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: A Cancer Journal for Clinicians, 71, 209-249.
|
[5]
|
Flanigan, R.C. and Yonover, P.M. (2001) The Role of Radical Nephrectomy in Metastatic Renal Cell Carcinoma. Seminars in Urologic Oncology, 19, 98-102.
|
[6]
|
Escudier, B., Szczylik, C., Hutson, T.E., Demkow, T., et al. (2009) Randomized Phase II Trial of First-Line Treatment with Sorafenib versus Interferon Alfa-2ain Patients with Metastatic Renal Cell Carcinoma. Journal of Clinical Oncology, 27, 1280-1289. https://doi.org/10.1200/JCO.2008.19.3342
|
[7]
|
Motzer, R.J., Hutson, T.E., Tomczak, P., et al. (2007) Sunitinib versus Interferon Alfa in Metastatic Renal-Cell Carcinoma. The New England Journal of Medicine, 256, 115-124. https://doi.org/10.1056/NEJMoa065044
|
[8]
|
Motzer, R.J., Escudier, B., Oudard, S., et al. (2008) Efficacy of Everolimus in Advanced Renal Cell Carcinoma: A Double-Blind, Randomised, Placebo-Controlled Phase III Trial. The Lancet, 372, 449-456.
https://doi.org/10.1016/S0140-6736(08)61039-9
|
[9]
|
Hudes, G., Carducci, M., Tomczak, P., et al. (2007) Temsirolimus, Interferon Alfa, or Both for Advanced Renal-Cell Carcinoma. The New England Journal of Medicine, 356, 2271-2281. https://doi.org/10.1056/NEJMoa066838
|
[10]
|
Massari, F., Di Nunno, V., Gatto, L., et al. (2018) Should CARMENA Really Change Our Attitude toward Cytoreductive Nephrectomy Inmetastatic Renal Cell Carcinoma? A Systematic Review and Meta-Analysis Evaluating Cytoreductive Nephrectomy in the Era of Targeted Therapy. Tar-geted Oncology, 13, 705-714.
https://doi.org/10.1007/s11523-018-0601-2
|
[11]
|
Conti, S.L., Thomas, I.C., Hagedorn, J.C., et al. (2014) Utilization of Cytoreductive Nephrectomy and Patient Survival in the Targeted Therapy Era. International Journal of Cancer, 134, 2245-2252. https://doi.org/10.1002/ijc.28553
|
[12]
|
Choueiri, T.K., Xie, W., Kollmannsberger, C., et al. (2011) The Impact of Cytoreductive Nephrectomy on Survival of Patients with Metastatic Renal Cell Carcinoma Receiving Vascular Endothelial Growth Factor Targeted Therapy. Journal of Urology, 185, 60-66. https://doi.org/10.1016/j.juro.2010.09.012
|
[13]
|
Flanigan, R.C., Salmon, S.E., Blumenstein, B.A., et al. (2001) Ne-phrectomy Followed by Interferon Alfa-2b Compared with Interferonalfa-2b Alone for Metastatic Renal-Cell Cancer. The New England Journal of Medicine, 345, 1655-1659.
https://doi.org/10.1056/NEJMoa003013
|
[14]
|
Mickisch, G.H., Garin, A., van Poppel, H., et al. (2001) Radical Ne-phrectomy plus Interferon-Alfa-Based Immunotherapy Compared with Interferon Alfa Alone in Metastatic Renal-Cell Carcinoma: A Randomised Trial. The Lancet, 358, 966-970. https://doi.org/10.1016/S0140-6736(01)06103-7
|
[15]
|
Motzer, R.J., Bukowski, R.M., Figlin, R.A., et al. (2008) Prognostic Nomogram for Sunitinib in Patients with Metastatic Renal Cell Carcinoma. Cancer, 113, 1552-1558. https://doi.org/10.1002/cncr.23776
|
[16]
|
Wood, C.G. (2001) Multimodal Approaches in the Management of Locally Advanced and Metastatic Renal Cell Carcinoma: Combining Surgery and Systemic Therapies to Improve Patient Out-come. Clinical Cancer Research, 13, 697s-702s. https://doi.org/10.1158/1078-0432.CCR-06-2109
|
[17]
|
Pierorazio, P.M., McKiernan, J.M., McCann, T.R., et al. (2007) Outcome after Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma Is Predicted by Fractional Percentage of Tumour Volume Removed. BJU International, 100, 755-759. https://doi.org/10.1111/j.1464-410X.2007.07108.x
|
[18]
|
Barbastefano, J., Garcia, J.A., Elson, P., et al. (2010) As-sociation of Percentage of Tumour Burden Removed with Debulking Nephrectomy and Progression Free Survivalin Pa-tients with Metastatic Renal Cell Carcinoma Treated with Vascular Endothelial Growth Factor Targeted Therapy. BJU In-ternational, 106, 1266-1269.
https://doi.org/10.1111/j.1464-410X.2010.09323.x
|
[19]
|
Hanna, N., Sun, M., Meyer, C.P., et al. (2016) Survival Analyses of Patients with Metastatic Renal Cancer Treated with Targeted Therapy with or without Cytoreductive Ne-phrectomy: A National Cancer Data Base Study. Journal of Clinical Oncology, 34, 3267-3275. https://doi.org/10.1200/JCO.2016.66.7931
|
[20]
|
Méjean, A., et al. (2018) Sunitinib Alone or after Nephrectomy in Metastatic Renal Cell Carcinoma. The New England Journal of Medicine, 379, 417-427. https://doi.org/10.1056/NEJMoa1803675
|
[21]
|
Kutikov, A., Uzzo, R.G., Caraway, A., et al. (2010) Use of Sys-temic Therapy and Factors Affecting Survival for Patients Undergoing Cytoreductive Nephrectomy. BJU International, 106, 218-223.
https://doi.org/10.1111/j.1464-410X.2009.09079.x
|
[22]
|
Abdollah, F., Sun, M., Thuret, R., et al. (2011) Mortality and Morbidity after Cytoreductive Nephrectomy for Metastatic Renal Cell Carcinoma: A Population-Based Study. Annals of Surgical Oncology, 18, 2988-2996.
https://doi.org/10.1245/s10434-011-1715-2
|
[23]
|
Maxwell, N.J., Saleem Amer, N., Rogers, E., et al. (2007) Renal Artery Embolisation in the Palliative Treatment of Renal Carcinoma. The British Journal of Radiology, 80, 96-102. https://doi.org/10.1259/bjr/31311739
|